search
Back to results

The Effects of Aspirin in Gestation and Reproduction (EAGeR)

Primary Purpose

Birth, Spontaneous Abortion

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
acetylsalicylic-acid (aspirin)
Folic acid
Sponsored by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Birth

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women experiencing one or two pregnancy losses at any point in gestation in the past that were not elective termination(s). At least one of these losses must be well documented by one of the following:

    • Sonogram demonstrating anembryonic loss, embryonic loss or fetal death.
    • Histologic confirmation of products of conception that were spontaneously passed per vagina or surgically obtained.
    • Hospital records of fetus delivery.
    • Late menses and positive serum hCG or positive urine hCG documented by hospital or clinic records followed by either a negative hospital/clinic pregnancy test or a decline in urinary hCG level over 3 days.
    • Home pregnancy tests without hCG confirmation from a healthcare provider (either serum or urine) will not be accepted.
  • No more than 5 pregnancies in total including the pregnancy loss(es).*
  • Up to two prior pregnancies that did not end in a loss.*

    *Women may have up to two pregnancies beyond 20 weeks that were not losses, two spontaneous pregnancy losses at any time in the past, and up to one therapeutic or elective termination (two therapeutic or elective terminations if no other pregnancies). Ectopic and molar pregnancies would, for the purpose of enrollment, be considered in the same category as therapeutic termination pregnancies. Women with more than two live births or those with more than two losses, regardless of the week of gestation of the loss, are excluded.

  • Presence of intact tubes (both), ovaries (both), and uterus.
  • Between 18 and 40 years of age at time of baseline visit.
  • Regular menstrual periods between 21 - 42 days in length (within the last 12 months). Regular menstrual periods are defined as no more than an 8-day difference between the woman's shortest and longest cycle.
  • No more than one missed menses in the past 12 months (other than those missed due to pregnancy or breastfeeding).
  • Actively trying to conceive with a male partner and not using contraception by the baseline visit.
  • Not currently pregnant at the baseline or randomization visits.
  • Ability and willingness to give informed consent.
  • Willingness to be randomized and to take daily study pills for 6 months to a possible 15 months

Exclusions Criteria:

  • Known allergies to aspirin or non-steroidal anti-inflammatory agents.
  • Clinical indication for anticoagulant therapy. These include prior or current thrombosis, antiphospholipid syndrome (APS) or known major thrombophilia.
  • Clinical indication for chronic use of NSAIDs such as rheumatoid arthritis.
  • Indication for additional folic acid supplementation, such as prior infant with neural tube defect (NTD), seizure disorder.
  • Medical contraindication to aspirin therapy. These include uncontrolled asthma, nasal polyps, bleeding disorders, or history of gastrointestinal ulcer.
  • Presence of major medical disorders (regardless of severity). These include diabetes, hypertension, systemic lupus erythematosus (SLE), untreated or active cancer (any cancer in remission or non-melanoma skin cancer is not included in the exclusion criteria), liver disease, renal disease, rheumatoid arthritis, cardiac disease, pulmonary disease other than mild asthma, neurologic disease requiring medical treatment, uncontrolled hypothyroidism, uncontrolled seizure disorder. Untreated vitamin B12 deficiency, severe anemia (Hct < 30%), hemophilia, gout, nasal polyps, among others.
  • Currently undergoing/planned use of assisted reproductive techniques during trial (IVF; IUI; Clomid).
  • History of infertility or sub-fertility. This includes any of the following:

    • No conception after ≥ 1 year of unprotected intercourse and actively trying to conceive.
    • Any prior medical treatment for infertility.
    • Prior treatment for known pelvic inflammatory disease.
    • Known male infertility or sperm abnormality (current partner).
    • Known tubal occlusion, anovulation, uterine abnormality, or endometriosis stage III or IV.
    • History of polycystic ovarian syndrome.
  • Presence of unstable mental disorder. These include bipolar illness, schizophrenia, uncontrolled depression, uncontrolled anxiety disorder.
  • Known current or recent alcohol abuse or illicit drug use.
  • Current diagnosis of sexually transmitted infection (STI) (temporary exclusion)

Sites / Locations

  • University of Colorado, Denver School of Medicine, Department of Obstetrics and Gynecology
  • Women's Health Research Center, Department of Social and Preventive Medicine, University at Buffalo
  • Moses Taylor Hospital
  • University of Utah Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Aspirin

Placebo

Arm Description

81mg of low-dose aspirin plus 400micrograms of folic acid.

400micrograms of folic acid.

Outcomes

Primary Outcome Measures

Live Birth
Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff .

Secondary Outcome Measures

hCG Recognized Pregnancy
Clinically Recognized Pregnancy
Early Pregnancy Loss (EPL)
Implantation failures
Pregnancy Losses Occurring Less Than 10 Weeks
Includes preembryonic and embryonic losses (exclusive of implantation failures)
Fetal Pregnancy Loss
Stillbirth
Ectopic Pregnancy
Molar Pregnancy
Preeclampsia
Small for Gestational Age Infant
birthweight
Preterm Birth
Abnormal Fetal Testing
Fetal Intolerance of Labor
Abruption
Partial or complete abruption (ie, premature separation of the placenta)

Full Information

First Posted
April 27, 2007
Last Updated
December 9, 2016
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT00467363
Brief Title
The Effects of Aspirin in Gestation and Reproduction
Acronym
EAGeR
Official Title
The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
June 2007 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
July 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.
Detailed Description
Despite the fundamental nature of reproduction, for many it is a process fraught with frustration, inefficiency and imperfections, the effects of which can be severe. Infertility affects 10-15% of couples attempting to conceive. Among all women who conceive, the incidence of spontaneous abortion (SA) has been estimated to be between 15 and 31%, and in many cases the cause is unknown. Additionally, of the four million births yearly in the United States, between 8 and 15% will be born prematurely and experience increased morbidity and mortality as a result. An intervention with even a small absolute effect on any of these outcomes has great implications at the population level due to the large potential attributable benefit. One such potential intervention is low-dose acetylsalicylic-acid (aspirin). Aspirin has been a primary target of interest because of its anti-inflammatory, vasodilatory and platelet aggregation inhibition properties. To evaluate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortion, we are conducting a multi-site randomized controlled trial study with two sites and one data coordinating center. Women aged 18-40 currently trying to become pregnant and who have had a single spontaneous abortion in the past year will be eligible for the study. The recruitment goal is 1600 women. Participating women will be randomly assigned to one of two treatment groups. Those randomized to treatment will receive daily low-dose aspirin. Those randomized to placebo will receive daily placebo. Both groups will receive folic acid daily in accordance with recommendations from the U.S. Public Health Service for prevention of birth defects. The duration of treatment regimens (LDA and folic acid or placebo and folic acid) will be 6 menstrual cycles, with those who become pregnant continuing until the end of pregnancy. Monthly urine and blood samples will be collected and questionnaires administered.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Birth, Spontaneous Abortion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1228 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aspirin
Arm Type
Active Comparator
Arm Description
81mg of low-dose aspirin plus 400micrograms of folic acid.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
400micrograms of folic acid.
Intervention Type
Drug
Intervention Name(s)
acetylsalicylic-acid (aspirin)
Other Intervention Name(s)
aspirin
Intervention Description
81mg of low-dose aspirin plus 400micrograms of folic acid.
Intervention Type
Dietary Supplement
Intervention Name(s)
Folic acid
Intervention Description
400micrograms of folic acid.
Primary Outcome Measure Information:
Title
Live Birth
Description
Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff .
Time Frame
after delivery
Secondary Outcome Measure Information:
Title
hCG Recognized Pregnancy
Time Frame
within 8-weeks of gestation
Title
Clinically Recognized Pregnancy
Time Frame
8-weeks
Title
Early Pregnancy Loss (EPL)
Description
Implantation failures
Time Frame
8 weeks
Title
Pregnancy Losses Occurring Less Than 10 Weeks
Description
Includes preembryonic and embryonic losses (exclusive of implantation failures)
Time Frame
less than 10-weeks
Title
Fetal Pregnancy Loss
Time Frame
until 40 weeks
Title
Stillbirth
Time Frame
40 weeks
Title
Ectopic Pregnancy
Time Frame
within 6 weeks
Title
Molar Pregnancy
Time Frame
8 weeks
Title
Preeclampsia
Time Frame
until delivery
Title
Small for Gestational Age Infant
Description
birthweight
Time Frame
until delivery
Title
Preterm Birth
Time Frame
until delivery
Title
Abnormal Fetal Testing
Time Frame
8 weeks
Title
Fetal Intolerance of Labor
Time Frame
until delivery
Title
Abruption
Description
Partial or complete abruption (ie, premature separation of the placenta)
Time Frame
until delivery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women experiencing one or two pregnancy losses at any point in gestation in the past that were not elective termination(s). At least one of these losses must be well documented by one of the following: Sonogram demonstrating anembryonic loss, embryonic loss or fetal death. Histologic confirmation of products of conception that were spontaneously passed per vagina or surgically obtained. Hospital records of fetus delivery. Late menses and positive serum hCG or positive urine hCG documented by hospital or clinic records followed by either a negative hospital/clinic pregnancy test or a decline in urinary hCG level over 3 days. Home pregnancy tests without hCG confirmation from a healthcare provider (either serum or urine) will not be accepted. No more than 5 pregnancies in total including the pregnancy loss(es).* Up to two prior pregnancies that did not end in a loss.* *Women may have up to two pregnancies beyond 20 weeks that were not losses, two spontaneous pregnancy losses at any time in the past, and up to one therapeutic or elective termination (two therapeutic or elective terminations if no other pregnancies). Ectopic and molar pregnancies would, for the purpose of enrollment, be considered in the same category as therapeutic termination pregnancies. Women with more than two live births or those with more than two losses, regardless of the week of gestation of the loss, are excluded. Presence of intact tubes (both), ovaries (both), and uterus. Between 18 and 40 years of age at time of baseline visit. Regular menstrual periods between 21 - 42 days in length (within the last 12 months). Regular menstrual periods are defined as no more than an 8-day difference between the woman's shortest and longest cycle. No more than one missed menses in the past 12 months (other than those missed due to pregnancy or breastfeeding). Actively trying to conceive with a male partner and not using contraception by the baseline visit. Not currently pregnant at the baseline or randomization visits. Ability and willingness to give informed consent. Willingness to be randomized and to take daily study pills for 6 months to a possible 15 months Exclusions Criteria: Known allergies to aspirin or non-steroidal anti-inflammatory agents. Clinical indication for anticoagulant therapy. These include prior or current thrombosis, antiphospholipid syndrome (APS) or known major thrombophilia. Clinical indication for chronic use of NSAIDs such as rheumatoid arthritis. Indication for additional folic acid supplementation, such as prior infant with neural tube defect (NTD), seizure disorder. Medical contraindication to aspirin therapy. These include uncontrolled asthma, nasal polyps, bleeding disorders, or history of gastrointestinal ulcer. Presence of major medical disorders (regardless of severity). These include diabetes, hypertension, systemic lupus erythematosus (SLE), untreated or active cancer (any cancer in remission or non-melanoma skin cancer is not included in the exclusion criteria), liver disease, renal disease, rheumatoid arthritis, cardiac disease, pulmonary disease other than mild asthma, neurologic disease requiring medical treatment, uncontrolled hypothyroidism, uncontrolled seizure disorder. Untreated vitamin B12 deficiency, severe anemia (Hct < 30%), hemophilia, gout, nasal polyps, among others. Currently undergoing/planned use of assisted reproductive techniques during trial (IVF; IUI; Clomid). History of infertility or sub-fertility. This includes any of the following: No conception after ≥ 1 year of unprotected intercourse and actively trying to conceive. Any prior medical treatment for infertility. Prior treatment for known pelvic inflammatory disease. Known male infertility or sperm abnormality (current partner). Known tubal occlusion, anovulation, uterine abnormality, or endometriosis stage III or IV. History of polycystic ovarian syndrome. Presence of unstable mental disorder. These include bipolar illness, schizophrenia, uncontrolled depression, uncontrolled anxiety disorder. Known current or recent alcohol abuse or illicit drug use. Current diagnosis of sexually transmitted infection (STI) (temporary exclusion)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enrique F Schisterman, PhD
Organizational Affiliation
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jean Wactawski-Wende, PhD
Organizational Affiliation
University at Buffalo
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Silver, MD
Organizational Affiliation
University of Utah
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Noya Galai, PhD
Organizational Affiliation
University of Haifa
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Janet Townsend, M.D.
Organizational Affiliation
The Commonwealth Medical College
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anne Lynch, M.D.
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado, Denver School of Medicine, Department of Obstetrics and Gynecology
City
Denver
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Women's Health Research Center, Department of Social and Preventive Medicine, University at Buffalo
City
Buffalo
State/Province
New York
ZIP/Postal Code
14260
Country
United States
Facility Name
Moses Taylor Hospital
City
Scranton
State/Province
Pennsylvania
ZIP/Postal Code
18510
Country
United States
Facility Name
University of Utah Medical Center
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
35972454
Citation
Schliep KC, Hinkle SN, Kim K, Sjaarda LA, Silver RM, Stanford JB, Purdue-Smithe A, Plowden TC, Schisterman EF, Mumford SL. Prospectively assessed perceived stress associated with early pregnancy losses among women with history of pregnancy loss. Hum Reprod. 2022 Sep 30;37(10):2264-2274. doi: 10.1093/humrep/deac172.
Results Reference
derived
PubMed Identifier
35386497
Citation
Zolton JR, Sjaarda LA, Mumford SL, Holland TL, Kim K, Flannagan KS, Yisahak SF, Hinkle SN, Connell MT, White MV, Perkins NJ, Silver RM, Hill MJ, DeCherney AH, Schisterman EF. Preconception hemoglobin A1c concentration in healthy women is not associated with fecundability or pregnancy loss. F S Rep. 2022 Jan 20;3(1):39-46. doi: 10.1016/j.xfre.2022.01.002. eCollection 2022 Mar.
Results Reference
derived
PubMed Identifier
35262718
Citation
Zhong Y, Brooks MM, Kennedy EH, Bodnar LM, Naimi AI. Use of Machine Learning to Estimate the Per-Protocol Effect of Low-Dose Aspirin on Pregnancy Outcomes: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022 Mar 1;5(3):e2143414. doi: 10.1001/jamanetworkopen.2021.43414. Erratum In: JAMA Netw Open. 2022 Apr 1;5(4):e229172.
Results Reference
derived
PubMed Identifier
35030239
Citation
Purdue-Smithe AC, Kim K, Schliep KC, DeVilbiss EA, Hinkle SN, Ye A, Perkins NJ, Sjaarda LA, Silver RM, Schisterman EF, Mumford SL. Preconception caffeine metabolites, caffeinated beverage intake, and fecundability. Am J Clin Nutr. 2022 Apr 1;115(4):1227-1236. doi: 10.1093/ajcn/nqab435.
Results Reference
derived
PubMed Identifier
34477845
Citation
Purdue-Smithe AC, Kim K, Andriessen VC, Pollack AZ, Sjaarda LA, Silver RM, Schisterman EF, Mumford SL. Preconception leukocyte telomere length and pregnancy outcomes among women with demonstrated fecundity. Hum Reprod. 2021 Nov 18;36(12):3122-3130. doi: 10.1093/humrep/deab201.
Results Reference
derived
PubMed Identifier
33864070
Citation
Alkhalaf Z, Kim K, Kuhr DL, Radoc JG, Purdue-Smithe A, Pollack AZ, Yisahak SF, Silver RM, Thoma M, Kissell K, Perkins NJ, Sjaarda LA, Mumford SL. Markers of vitamin D metabolism and premenstrual symptoms in healthy women with regular cycles. Hum Reprod. 2021 Jun 18;36(7):1808-1820. doi: 10.1093/humrep/deab089.
Results Reference
derived
PubMed Identifier
33493011
Citation
Naimi AI, Perkins NJ, Sjaarda LA, Mumford SL, Platt RW, Silver RM, Schisterman EF. The Effect of Preconception-Initiated Low-Dose Aspirin on Human Chorionic Gonadotropin-Detected Pregnancy, Pregnancy Loss, and Live Birth : Per Protocol Analysis of a Randomized Trial. Ann Intern Med. 2021 May;174(5):595-601. doi: 10.7326/M20-0469. Epub 2021 Jan 26.
Results Reference
derived
PubMed Identifier
33421071
Citation
Mumford SL, Flannagan KS, Radoc JG, Sjaarda LA, Zolton JR, Metz TD, Plowden TC, Perkins NJ, DeVilbiss EA, Andriessen VC, A C PS, Kim K, Yisahak SF, Freeman JR, Alkhalaf Z, Silver RM, Schisterman EF. Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth and pregnancy loss. Hum Reprod. 2021 Apr 20;36(5):1405-1415. doi: 10.1093/humrep/deaa355.
Results Reference
derived
PubMed Identifier
33311959
Citation
Flannagan KS, Mumford SL, Sjaarda LA, Radoc JG, Perkins NJ, Andriessen VC, Zolton JR, Silver RM, Schisterman EF. Is opioid use safe in women trying to conceive? Epidemiology. 2020 Nov;31(6):844-851. doi: 10.1097/EDE.0000000000001247.
Results Reference
derived
PubMed Identifier
33066974
Citation
Sjaarda LA, Radoc JG, Flannagan KS, Mumford SL, Kim K, Perkins NJ, Silver RM, Schisterman EF. Urinary selective serotonin reuptake inhibitors across critical windows of pregnancy establishment: a prospective cohort study of fecundability and pregnancy loss. Fertil Steril. 2020 Dec;114(6):1278-1287. doi: 10.1016/j.fertnstert.2020.06.037. Epub 2020 Oct 14.
Results Reference
derived
PubMed Identifier
32896390
Citation
Evans MB, Nobles CJ, Kim K, Hill MJ, DeCherney AH, Silver RM, Mumford SL, Sjaarda LA, Perkins NJ, Schisterman EF. Low-dose aspirin in reproductive health: effects on menstrual cycle characteristics. Fertil Steril. 2020 Dec;114(6):1263-1270. doi: 10.1016/j.fertnstert.2020.06.022. Epub 2020 Sep 4.
Results Reference
derived
PubMed Identifier
32755413
Citation
Nobles CJ, Mendola P, Mumford SL, Silver RM, Kim K, Andriessen VC, Connell M, Sjaarda L, Perkins NJ, Schisterman EF. Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension. Hypertension. 2020 Sep;76(3):922-929. doi: 10.1161/HYPERTENSIONAHA.120.14875. Epub 2020 Aug 3.
Results Reference
derived
PubMed Identifier
32358837
Citation
Hamulyak EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2.
Results Reference
derived
PubMed Identifier
32354366
Citation
Yeung EH, Guan W, Zeng X, Salas LA, Mumford SL, de Prado Bert P, van Meel ER, Malmberg A, Sunyer J, Duijts L, Felix JF, Czamara D, Hamalainen E, Binder EB, Raikkonen K, Lahti J, London SJ, Silver RM, Schisterman EF. Cord blood DNA methylation reflects cord blood C-reactive protein levels but not maternal levels: a longitudinal study and meta-analysis. Clin Epigenetics. 2020 Apr 30;12(1):60. doi: 10.1186/s13148-020-00852-2.
Results Reference
derived
PubMed Identifier
32192592
Citation
Russo LM, Whitcomb BW, Freeman JR, Mumford SL, Sjaarda LA, Perkins NJ, Schliep KC, Grewal J, Silver RM, Schisterman EF. Physical activity and incidence of subclinical and clinical pregnancy loss: a secondary analysis in the effects of aspirin in gestation and reproduction randomized trial. Fertil Steril. 2020 Mar;113(3):601-608.e1. doi: 10.1016/j.fertnstert.2019.10.027.
Results Reference
derived
PubMed Identifier
31858113
Citation
Robinson SL, Mumford SL, Guan W, Zeng X, Kim K, Radoc JG, Trinh MH, Flannagan K, Schisterman EF, Yeung E. Maternal fatty acid concentrations and newborn DNA methylation. Am J Clin Nutr. 2020 Mar 1;111(3):613-621. doi: 10.1093/ajcn/nqz311.
Results Reference
derived
PubMed Identifier
30998747
Citation
Agrawala S, Sjaarda LA, Omosigho UR, Perkins NJ, Silver RM, Mumford SL, Connell MT, Naimi AI, Halvorson LM, Schisterman EF. Effect of preconception low dose aspirin on pregnancy and live birth according to socioeconomic status: A secondary analysis of a randomized clinical trial. PLoS One. 2019 Apr 18;14(4):e0200533. doi: 10.1371/journal.pone.0200533. eCollection 2019.
Results Reference
derived
PubMed Identifier
30124893
Citation
Mumford SL, Browne RW, Kim K, Nichols C, Wilcox B, Silver RM, Connell MT, Holland TL, Kuhr DL, Omosigho UR, Perkins NJ, Radin R, Sjaarda LA, Schisterman EF. Preconception Plasma Phospholipid Fatty Acids and Fecundability. J Clin Endocrinol Metab. 2018 Dec 1;103(12):4501-4510. doi: 10.1210/jc.2018-00448.
Results Reference
derived
PubMed Identifier
29859909
Citation
Mumford SL, Garbose RA, Kim K, Kissell K, Kuhr DL, Omosigho UR, Perkins NJ, Galai N, Silver RM, Sjaarda LA, Plowden TC, Schisterman EF. Association of preconception serum 25-hydroxyvitamin D concentrations with livebirth and pregnancy loss: a prospective cohort study. Lancet Diabetes Endocrinol. 2018 Sep;6(9):725-732. doi: 10.1016/S2213-8587(18)30153-0. Epub 2018 May 31.
Results Reference
derived
PubMed Identifier
29771194
Citation
Gibbins KJ, Mumford SL, Sjaarda LA, Branch DW, Perkins NJ, Ye A, Schisterman EF, Silver RM. Preconception antiphospholipid antibodies and risk of subsequent early pregnancy loss. Lupus. 2018 Aug;27(9):1437-1445. doi: 10.1177/0961203318776089. Epub 2018 May 17.
Results Reference
derived
PubMed Identifier
29648647
Citation
Russo LM, Whitcomb BW, Mumford SL, Hawkins M, Radin RG, Schliep KC, Silver RM, Perkins NJ, Kim K, Omosigho UR, Kuhr DL, Holland TL, Sjaarda LA, Schisterman EF. A prospective study of physical activity and fecundability in women with a history of pregnancy loss. Hum Reprod. 2018 Jul 1;33(7):1291-1298. doi: 10.1093/humrep/dey086.
Results Reference
derived
PubMed Identifier
29610265
Citation
Nobles CJ, Mendola P, Mumford SL, Naimi AI, Yeung EH, Kim K, Park H, Wilcox B, Silver RM, Perkins NJ, Sjaarda L, Schisterman EF. Preconception Blood Pressure Levels and Reproductive Outcomes in a Prospective Cohort of Women Attempting Pregnancy. Hypertension. 2018 May;71(5):904-910. doi: 10.1161/HYPERTENSIONAHA.117.10705. Epub 2018 Apr 2.
Results Reference
derived
PubMed Identifier
29548752
Citation
Kuhr DL, Sjaarda LA, Alkhalaf Z, Omosigho UR, Connell MT, Silver RM, Kim K, Perkins NJ, Holland TL, Plowden TC, Schisterman EF, Mumford SL. Vitamin D is associated with bioavailability of androgens in eumenorrheic women with prior pregnancy loss. Am J Obstet Gynecol. 2018 Jun;218(6):608.e1-608.e6. doi: 10.1016/j.ajog.2018.03.012. Epub 2018 Mar 13.
Results Reference
derived
PubMed Identifier
29428315
Citation
Sjaarda LA, Mumford SL, Kuhr DL, Holland TL, Silver RM, Plowden TC, Perkins NJ, Schisterman EF. Association of testosterone and antimullerian hormone with time to pregnancy and pregnancy loss in fecund women attempting pregnancy. Fertil Steril. 2018 Mar;109(3):540-548.e1. doi: 10.1016/j.fertnstert.2017.11.014. Epub 2018 Feb 7.
Results Reference
derived
PubMed Identifier
29317123
Citation
Radin RG, Sjaarda LA, Silver RM, Nobles CJ, Mumford SL, Perkins NJ, Wilcox BD, Pollack AZ, Schliep KC, Plowden TC, Schisterman EF. C-Reactive protein in relation to fecundability and anovulation among eumenorrheic women. Fertil Steril. 2018 Feb;109(2):232-239.e1. doi: 10.1016/j.fertnstert.2017.10.025. Epub 2018 Jan 6.
Results Reference
derived
PubMed Identifier
28917612
Citation
Plowden TC, Schisterman EF, Sjaarda LA, Perkins NJ, Silver R, Radin R, Kim K, Galai N, DeCherney AH, Mumford SL. Thyroid-stimulating hormone, anti-thyroid antibodies, and pregnancy outcomes. Am J Obstet Gynecol. 2017 Dec;217(6):697.e1-697.e7. doi: 10.1016/j.ajog.2017.09.001. Epub 2017 Sep 14.
Results Reference
derived
PubMed Identifier
28333301
Citation
Pugh SJ, Schisterman EF, Browne RW, Lynch AM, Mumford SL, Perkins NJ, Silver R, Sjaarda L, Stanford JB, Wactawski-Wende J, Wilcox B, Grantz KL. Preconception maternal lipoprotein levels in relation to fecundability. Hum Reprod. 2017 May 1;32(5):1055-1063. doi: 10.1093/humrep/dex052.
Results Reference
derived
PubMed Identifier
28323989
Citation
Sjaarda LA, Radin RG, Silver RM, Mitchell E, Mumford SL, Wilcox B, Galai N, Perkins NJ, Wactawski-Wende J, Stanford JB, Schisterman EF. Preconception Low-Dose Aspirin Restores Diminished Pregnancy and Live Birth Rates in Women With Low-Grade Inflammation: A Secondary Analysis of a Randomized Trial. J Clin Endocrinol Metab. 2017 May 1;102(5):1495-1504. doi: 10.1210/jc.2016-2917.
Results Reference
derived
PubMed Identifier
27754808
Citation
Radin RG, Sjaarda LA, Perkins NJ, Silver RM, Chen Z, Lesher LL, Galai N, Wactawski-Wende J, Mumford SL, Schisterman EF. Low-Dose Aspirin and Sporadic Anovulation in the EAGeR Randomized Trial. J Clin Endocrinol Metab. 2017 Jan 1;102(1):86-92. doi: 10.1210/jc.2016-2095.
Results Reference
derived
PubMed Identifier
27669539
Citation
Hinkle SN, Mumford SL, Grantz KL, Silver RM, Mitchell EM, Sjaarda LA, Radin RG, Perkins NJ, Galai N, Schisterman EF. Association of Nausea and Vomiting During Pregnancy With Pregnancy Loss: A Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med. 2016 Nov 1;176(11):1621-1627. doi: 10.1001/jamainternmed.2016.5641.
Results Reference
derived
PubMed Identifier
26707905
Citation
Zarek SM, Mitchell EM, Sjaarda LA, Mumford SL, Silver RM, Stanford JB, Galai N, Schliep KC, Radin RG, Plowden TC, DeCherney AH, Schisterman EF. Antimullerian hormone and pregnancy loss from the Effects of Aspirin in Gestation and Reproduction trial. Fertil Steril. 2016 Apr;105(4):946-952.e2. doi: 10.1016/j.fertnstert.2015.12.003. Epub 2015 Dec 17.
Results Reference
derived
PubMed Identifier
26406293
Citation
Zarek SM, Mitchell EM, Sjaarda LA, Mumford SL, Silver RM, Stanford JB, Galai N, White MV, Schliep KC, DeCherney AH, Schisterman EF. Is Anti-Mullerian Hormone Associated With Fecundability? Findings From the EAGeR Trial. J Clin Endocrinol Metab. 2015 Nov;100(11):4215-21. doi: 10.1210/jc.2015-2474. Epub 2015 Sep 25.
Results Reference
derived
PubMed Identifier
26280577
Citation
Radin RG, Mumford SL, Silver RM, Lesher LL, Galai N, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Simhan HN, Sjaarda LA, Perkins NJ, Zarek SM, Schliep KC, Schisterman EF. Sex ratio following preconception low-dose aspirin in women with prior pregnancy loss. J Clin Invest. 2015 Sep;125(9):3619-26. doi: 10.1172/JCI82357. Epub 2015 Aug 17.
Results Reference
derived
PubMed Identifier
25751215
Citation
Silver RM, Ahrens K, Wong LF, Perkins NJ, Galai N, Lesher LL, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Mumford SL, Sjaarda L, Schisterman EF. Low-dose aspirin and preterm birth: a randomized controlled trial. Obstet Gynecol. 2015 Apr;125(4):876-884. doi: 10.1097/AOG.0000000000000736.
Results Reference
derived
PubMed Identifier
25710565
Citation
Schisterman EF, Mumford SL, Schliep KC, Sjaarda LA, Stanford JB, Lesher LL, Wactawski-Wende J, Lynch AM, Townsend JM, Perkins NJ, Zarek SM, Tsai MY, Chen Z, Faraggi D, Galai N, Silver RM. Preconception low dose aspirin and time to pregnancy: findings from the effects of aspirin in gestation and reproduction randomized trial. J Clin Endocrinol Metab. 2015 May;100(5):1785-91. doi: 10.1210/jc.2014-4179. Epub 2015 Feb 24.
Results Reference
derived
PubMed Identifier
24702835
Citation
Schisterman EF, Silver RM, Lesher LL, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Perkins NJ, Mumford SL, Galai N. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet. 2014 Jul 5;384(9937):29-36. doi: 10.1016/S0140-6736(14)60157-4. Epub 2014 Apr 2.
Results Reference
derived
Links:
URL
https://www.nichd.nih.gov/about/org/diphr/eb/research/pages/effects-aspirin.aspx
Description
EAGeR Trial Home Page

Learn more about this trial

The Effects of Aspirin in Gestation and Reproduction

We'll reach out to this number within 24 hrs